Asthma in Italy according to patients and physicians: comments on data collected in the multi-country study APPaRENT2

Abstract

APPaRENT2 was a multi-country, cross-sectional, online survey of patients with asthma and physicians conducted in five countries (Argentina, Brazil, France, Mexico, and Italy), aimed at assessing physicians’ and patients’ preferred treatment strategies and goals. Education level, age, and place of residence differed between European and Latin American patients; furthermore, most Italian doctors worked within the Public Health Service. For the purpose of identifying the critical issues in the management of asthma in Italy, the data were analysed in greater detail, comparing those collected in Italy with those from Latin American countries and those provided by Italian patients and doctors. The data are reported as frequencies or means. The differences found in comparing data were not analysed for statistical significance, given the absence of any a priori hypothesis in the original paper. The Italian results were consistently within the range of the Latin American countries’ results. In Italy, despite the physicians’ prioritization of symptom control, many patients had poor asthma control but gave a surprisingly optimistic evaluation of their disease, given the high frequency of symptoms and limitations in everyday life. Physicians and patients had quite different evaluations of symptoms and outcomes of asthma. Finally, the combination of ICS/LABA with SABA as needed was the preferred treatment compared with the maintenance and reliever therapy (MART) strategy, suggested as preferential in the Global Initiative for Asthma (GINA) document. In conclusion, the absence of shared assessments and expectations between doctors and patients appears to be the primary issue to address in order to improve asthma treatment in Italy.

Keywords

burden of asthma / severity of asthma / management of asthma / asthma in community medicine / survey

References

[1] Chapman KR, Canonica GW, Lavoie KL, Nenasheva N, Garcia G, Bosnic—Anticevich S, et al. Patients’ and physicians’ perspectives on the burden and management of asthma: Results from the APPaRENT 2 study. Respir Med. 2022; 201:106948.

[2] Global strategy for asthma management and prevention [Internet]. Global Initiative for Asthma; c2021 [cited 2025 Oct 25]. Available from: https://ginasthma.org/wp—content/uploads/2023/04/GINA—Main—Report—2021—V2—WMSA.pdf

[3] O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, et al. Inhaled Combined Budesonide—Formoterol as Needed in Mild Asthma. N Engl J Med. 2018; 378:1865—76.

[4] Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, et al. As—Needed Budesonide—Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018; 378:1877-87.

[5] Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled Trial of Budesonide—Formoterol as Needed for Mild Asthma. N Engl J Med. 2019; 380:2020—30.

[6] Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, et al. Budesonide—formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52—week, open—label, multicentre, superiority, randomised controlled trial. Lancet. 2019; 394:919-28.

[7] Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol. 2010; 125:600—8.

[8] Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004; 113:59-65.

[9] Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14:902-7.

[10] The Medicines Utilisation Monitoring Centre . National Report on Medicines use in Italy. Year 2022 [Internet]. Italian Medicines Agency (AIFA); [cited 2025 Oct 25]. Available from: https://www.aifa.gov.it

[11] Sui M, Cheng M, Zhang S, Wang Y, Yan Q, Yang Q, et al. The digitized chronic disease management model: scalable strategies for implementing standardized healthcare and big data analytics in Shanghai. Front Big Data. 2023; 6:1241296.

[12] Lebina L, Kawonga M, Oni T, Kim HY, Alaba OA. The cost and cost implications of implementing the integrated chronic disease management model in South Africa. PLoS One. 2020; 15:e0235429.

[13] Mahomed OH, Asmall S, Voce A. Sustainability of the integrated chronic disease management model at primary care clinics in South Africa. Afr J Prim Health Care Fam Med. 2016; 8:e1-7.

[14] Ferrante E, Muzzolon R, Fuso L, Corbo GM, Pistelli R, Ciappi G. Bronchial asthma: still an inadequately assessed and improperly treated disease. J Asthma. 1994; 31:117-21.

[15] Ferrante E, Muzzolon R, Fuso L, Corbo GM, Pistelli R, Ciappi G. Undertreatment of bronchial asthma in a nonselected population. J Allergy Clin Immunol. 1998; 101:570-1.